Publication Name	World Journal of Gastroenterology
Manuscript ID	103267
Country	India

Received	2024-11-14 10:10
Peer-Review Started	2024-11-14 10:10
To Make the First Decision
Return for Revision	2025-02-26 02:23
Revised	2025-03-13 06:42
Second Decision	2025-03-19 02:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-03-19 06:56
Articles in Press	2025-03-19 06:56
Publication Fee Transferred
Edit the Manuscript by Language Editor	2025-03-23 23:02
Typeset the Manuscript	2025-04-01 01:26
Publish the Manuscript Online	2025-04-11 02:19

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Immune therapies in intermediate-advanced unresectable hepatocellular carcinoma: Changing the therapeutic landscape
Manuscript Source	Invited Manuscript
All Author List	Sagnik Biswas and Arghya Samanta
Funding Agency and Grant Number
Corresponding Author	Arghya Samanta, Assistant Professor, MD, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India. arghyasamanta2905@gmail.com
Key Words	Intermediate-advanced stage hepatocellular carcinoma; Immunotherapy; Tyrosine kinase inhibitors; Sorafenib
Core Tip	Hepatocellular carcinoma is often identified in advanced cases and is associated with poor survival. Combination therapies such as immune checkpoint inhibitors or tyrosine kinase inhibitors along with interventional therapies are proposed to enhance the sensitivity of these tumors to drug therapy increasing rates of clinical response. While such an approach has a robust pathophysiological basis, the clinical data on this approach is evolving and needs large multicentric studies. Results from early observational data on combination therapies is encouraging.
Publish Date	2025-04-11 02:19
Citation	<p>Biswas S, Samanta A. Immune therapies in intermediate-advanced unresectable hepatocellular carcinoma: Changing the therapeutic landscape. <i>World J Gastroenterol</i> 2025; 31(14): 103267</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i14/103267.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i14.103267

Full Article (PDF)	WJG-31-103267-with-cover.pdf
Manuscript File	103267_Auto_Edited_075911.docx
Answering Reviewers	103267-answering-reviewers.pdf
Audio Core Tip	103267-audio.mp3
Conflict-of-Interest Disclosure Form	103267-conflict-of-interest-statement.pdf
Copyright License Agreement	103267-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	103267-non-native-speakers.pdf
Peer-review Report	103267-peer-reviews.pdf
Scientific Misconduct Check	103267-scientific-misconduct-check.png
Scientific Editor Work List	103267-scientific-editor-work-list.pdf
CrossCheck Report	103267-crosscheck-report.pdf